mix test result possibl equiti rais
diagnos patholog perform despit strong increas
test volum averag australia estim industri patholog
volum fallen yoy mid-march result lower gp attend
deferr elect surgeri patholog estim us volum declin
yoy mid-march eas social restrict includ elect
surgeri australia us posit shl expect slow return
receiv elect healthcar turn drive stronger patholog volum
fix cost remain issu earn lower earn
due stronger declin industri volum previous expect
assum reduct patholog revenu week mid-march end april
reduct patholog revenu may-jun opex fix
employe expens expect sharp fall patholog ebit margin bp
rais equiti possibl shl pursu growth opportun base case
estim net debt/ebtida reach ex lower
bear case scenario assum sustain declin patholog
revenu remaind net debt/ebitda rise vs coven
view believ equiti rais need shl
suffici liquid yet possibl shl may seek rais equiti ensur
appropri gear pursu growth opportun believ pandem
may catalyst consolid lab particularli us industri
volum declin excess view like shl use current market
disrupt advanc growth strategi us anatom patholog market
maintain outperform rate lower target price
lower earn shl earn impact long-term demand
shl servic remain intact return full volum like take time covid-
restrict eas gradual believ shl scale global presenc support
growth medium term
valuat metric
total return forecast perspect
chang previou ep
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
price book
return equiti
return asset
return invest cap
net debt ebitda
capital-expenditure sale
capital-expenditure depr
 asx close
spot exchang rate
price
profit tax
profit tax
unusu item tax
chang work capit
cash non-cash item
movement cash/equival
lower estim sever impact
shl withdrew earn guidanc late march due creat signific
uncertainti around volum earn perform shl provid trade
updat sinc summaris key publicli avail data point assist earn
estim shl region
hl patholog revenu order overal includ covid
test start show sign stabil recoveri april
royal colleg pathologist australasia privat commun
patholog test current done due peopl visit medic
practition thu patholog sampl collect equat
australian everi day similar proport patient new zealand
smaller reduct also occur public sector april
reimburs april medicar reimburs test increas
privat patholog provid vs previous
medicar data march show materi declin patholog volum outlay
surprisingli non-hospit patient episod initi proxi gp/specialist
patholog referr declin yoy march patholog outlay increas yoy
view volatil monthli data make reflect industri perform
quest diagnost overal test volum declin last two
week march march april volum declin continu intensifi
see volum declin stabilis expect volum ex-covid
test april
labcorp test volum declin versu compani normal daili
level end quarter start see littl bit less declin go
toward end month countri get back run would
expect start see less declin summer would expect get
toward end year lot volum come back alway come back
fact import health april
abbott laboratori sharp deterior routin test broadli across europ
us last week march havent seen rebound start
see sign stabilis april
american clinic laboratori associ cost suppli increas
laboratori see substanti declin test patient visit
physician plummet elect surgeri screen routin care servic
reimburs april medicar reimburs high through-put
test increas previous
serolog test shl start serolog test us germani
stage factor signific upsid
caj volum april
hl revenu april
medicar data march show industri radiolog volum industri
radiolog outlay yoy mri ct volum declin modestli mri
yoy ct
conflict view gp attend key industri player
caj gp attend april
hl telehealth make gp attend gp attend averag
medicar data march part govern respons
introduc temporari mb telehealth servic made access
patient previous telehealth elig remot commun
standard gp attend telehealth account volum telehealth
volum yoy without telehealth volum yoy
figur telehealth keep gp attend growth
figur account volum
chart credit suiss estim medicar
brought signific disrupt privat patholog declin routin
test deferr elect surgeri howev gener eas restrict
posit particularli elect surgeri begin resum australia throughout
select state within us undoubtedli take time lab volum return
pre-covid level eas restrict happen sooner anticip
make follow assumpt
australia patholog forecast reduct patholog revenu week
mid-march end april reduct patholog revenu may-jun
assum util telehealth gp referr continu
us patholog forecast reduct patholog revenu week mid-
march end april reduct patholog revenu may-jun assum
volum return elect surgeri start prompt peopl visit doctor
eu patholog forecast reduct patholog revenu week mid-
march end april reduct patholog revenu may-jun
imag forecast reduct patholog revenu week mid-march
end april reduct patholog revenu may-jun assum australia
patholog return faster rate vs radiolog
cost employe make oper cost shl target
signific reduct casual staff cost howev given shl readi
volum return believ cost reduct off-set volum declin
lower patholog ebit margin
dividend given sharp declin earn temporarili reduc dividend pay-out
ratio
result assumpt lower earn
make major chang earn assumpt believ strong demand lab
servic remain shl scale global presenc allow benefit volum
return pre-covid level
equiti rais tabl
rhc rais equiti amidst pandem question also
ask whether shl also need rais given sharp deterior oper
condit due
suffici liquid get
shl strong balanc sheet cash commit credit facil avail
debt facil matur chf debt
expir figur detail shl debt matur profil liquid posit
despit materi drop expect volum shl fix cost base believ
suffici liquid see pandem current facil
reimburs test increas australia us shl
continu ramp test capac region shl also start serolog
test germani us provid anoth sourc revenu volum
return level
drawn debt
forecast net debt/ebitda lower
coven level net debt/ebitda bear case scenario assum
improv patholog volum remaind forecast net debt/ebitda
expand still coven level
view shl strong balanc sheet need rais equiti
howev may look rais equiti order pursu growth opportun particularli
aris us anatom market
au pathologyu pathologyeu ebitda ebitda growth npat npat growth debt/ebitda revenu return back level casebear case revenu declin week mid-march april revenu declin may-jun revenu declin week mid-march april revenu declin revenu declin week mid-march april revenu declin revenu declin week mid-march april revenu declin revenu declin mid-march end revenu declin mid-march end revenu declin mid-march end revenu declin mid-march end charl martineau pm univers toronto may
revenu segment
figur patholog ebitda
ebitda segment
chart compani data credit suiss estim
figur declin ebitda due
ebitda segment
figur ebit margin fall sharpli
figur forecast reduc pay-out ratio
dp dividend pay-out ratio
new total return forecast perspect chart help visual credit suiss consensu view compani return
within context forecast risk histor trade pattern
volatil calcul annualis standard deviat weekli total return seri past month illustr variabl
stock return word risk way think one would rather take forecast return stock
volatil stock volatil shade area show one standard deviat rang base past month volatil
statist term make number brave assumpt probabl share price end insid rang
hi-lo maximum minimum daili close price past week often handi know price momentum especi
stock trade close high low stock trade close peak momentum stock
consensu consensu suppli thomson reuter survey sell side research analyst collect dozen data
point ep dp sale target price roe mean averag target return shade area around
mean repres rang estim lowest highest estim aid visualis number import factor
rang analyst estim credit suiss estim stock sit rel consensu share price rel
consensu mean consensu rang target
return calcul capit gain plu forecast dividend yield net next month cs tgt use credit suiss
target price credit suiss forecast forward dividend gross frank consensu mean rang
use consensu target price consensu dividend forecast month forward
compani mention price
labcorp america lh
gretel janu certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
